# Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest A Bayesian Perspective

James M Brophy<sup>a,1,\*</sup>

<sup>a</sup>McGill University Health Center, Centre for Health Outcomes Research (CORE), 5252 Boul. de Maisonneuve West Room 2B.37, Montreal, H4A 3S5

#### Abstract

A recent randomized clinical trial reported in patients with refractory out-of-hospital cardiac arrest, extracorporeal CPR and conventional CPR had similar effects on survival with a favorable neurologic outcome. Herein, it is examined whether a Bayesian perspective allows any additional insights into the interpretation of this trial.

Keywords: extracorporeal CPR, Bayesian statistics

#### 1. Introduction

Out-of-hospital cardiac arrest is a frequent event and fortunately its devastating consequences can be partially mitigated by rapid commencement of basic life support with high-quality chest compressions and external defibrillation (conventional cardiopulmonary resuscitation (CPR)). However, there remains a substantial subset of individuals who do not respond rapidly to these measures and whether more invasive measures. Whether the addition of more aggressive measure including extracorporeal CPR (the addition of extracorporeal membrane oxygenation to standard advanced cardiac life support) can improve survival and diminish anoxic brain injury is a current topic of research. The largest randomized clinical trial (RCT) examining this question recently published their results  $^1$ . For the primary outcome, 30 day survival without significant neurological deficit, the authors observed an odds ratio of 1.4 (95% confidence interval, 0.5 to 3.5; P = 0.52) in favor of extracorporeal CPR for leading to their conclusion "In patients with refractory out-of-hospital cardiac arrest, extracorporeal CPR and conventional CPR had similar effects on survival with a favorable neurological outcome".  $^1$ 

This communication does not reiterate the many reasons to be wary of null hypothesis significance testing (NHST), p values and confidence intervals<sup>2</sup>. Rather it assumes the reader has perhaps heard that Bayesian methods mirror our intuitive learning process and is curious about its potential application to RCT interpretations.

Therefore the goal of this communication is to examine whether a Bayesian perspective permits additional insights into the specific clinical question regarding any added value of extracorporeal CPR following an out-of-hospital arrest in patients refractory to standard CPR.

### 2. Methods

The data for the primary outcome, 30 day survival with intact neurological status, based on an intention to treat (ITT) analysis was abstracted from the original INCEPTION trial <sup>1</sup> and used for the primary analysis.

 $<sup>^*</sup> Corresponding \ author$ 

Email address: james.brophy@mcgill.ca (James M Brophy)

<sup>&</sup>lt;sup>1</sup>JMB is a research scholar supported by Les Fonds de Recherche Québec Santé

The ITT analysis has the advantage of minimizing bias by preserving the prognostic balance afforded by randomization as well as assuring the validity of the statistical analyses. ITT assesses subjects based on the group they were initially (and randomly) allocated to, regardless of whether or not they dropped out, were fully adhered to the treatment or switched to an alternative treatment. ITT analyses can therefore be seen as a conservative estimate which mirrors clinical effectiveness. In contrast, a per protocol (PP) analysis involves a comparison of treatment groups in a trial that includes only those patients who completed the treatment they were originally allocated to. Similarly an "as treated" analysis considers only which treatments subjects received, regardless of their randomization status and protocol adherence. While both PP and as-treated analyses alone may lead to bias, in conjunction with an ITT analysis they may provide additional insights into efficacy and have also been examined from a Bayesian perspective.

Bayesian analytical approaches provide a number of benefits over the classical NHST approach, including parameter estimation accompanied by direct probability statements about parameters of interest (herein the risk of survival with intact neurological status), and the incorporation prior knowledge<sup>3,4</sup>.

These probability statements arise from the posterior distribution according to the following equation:

$$\label{eq:Posterior} Posterior = \frac{Probability\ of\ the\ data*Prior}{Normalizing\ Constant}$$

Therefore, in addition to the current data summarized by the probability of the data (likelihood function) one requires a prior probability distribution for each parameter. The mechanics of the Bayesian analyses were performed using the Stan programming language<sup>5</sup> through the R package rstanarm<sup>6</sup> and fit a logistic regression model with a single treatment parameter,  $\theta$ . Because our focus is the interpretation of the INCEPTION trial alone, our primary analysis used rstanarm's default vague parameter priors ( $log(\theta) \sim Normal[0, 2.50]$ , thereby assuring that the posterior distribution is dominated by the observed INCEPTION data.

The robustness of the Bayesian approach is often assessed by sensitivity analyses that examine the variation in the posterior probability as a function of the choice of different prior distributions. Using prior information also underscores the important advantage of Bayesian analyses to learn sequentially. There were two previous RCTs examining extracorporeal CPR[(author?) $^{7}$ ] and while the protocols are not identical, it may be reasonable to allow this data can serve as an informed prior which can be updated with the INCEPTION data. This prior information of the probability of success in each arm,  $X_i$ , can be summarized by a Beta distribution as follow

$$X_i \sim \mathrm{Beta}(\alpha_0,\beta_0)$$

where in the context of Bernoulli trials,  $\alpha$  can be interpreted as 1 + number of successes and  $\beta$  can be interpreted as 1 + number of failures. The mean and variance of this distribution are

$$\mu = \frac{\alpha}{\alpha + \beta}$$

$$\sigma^2 = \frac{\alpha\beta}{(\alpha+\beta)^2(\alpha+\beta+1)}$$

where  $\alpha$  and  $\beta$  are the number of successes and failures respectively. The difference between the two treatment arms of these previous studies can then serve as the prior information which in the Bayesian paradigm can be updated with the INCEPTION data to form a posterior distribution.

Posterior distributions are summarized with medians and 95% highest-density intervals (credible intervals), defined as the narrowest interval containing 95% of the probability density function  $^9$ . We not only calculated the posterior probability of any benefit (OR >1.00), but also of clinically meaningful benefits (defined as OR >1.10).

All analyses were executed within the integrated development environment of RStudio and the statistical code can be found on Github (https://github.com/brophyj/eCPR).

# 3. Results

The ITT data from the three pertinent trials is shown in Table 1. Performing a Bayesian analysis on the INCEPTION trial, using a vague prior, produces an odds ratio 1.32~(95% Credible Interval (CrI) 0.54 - 3.22). The closeness of this result to the original analysis confirms the lack if impact of the vague prior and shows this Bayesian analysis is dominated by the observed data.

### 4. Tables

Table 1: Table 1 Extracted ITT trial data

Trial	Fail CPR	Fail eCPR	Success CPR	Success eCPR
INCEPTION	52	56	10	14
ARREST	15	8	0	6
PRAGUE	108	86	24	38

### 5. Bayesian analysis

Attaching package: 'LearnBayes'

The following object is masked from 'package:rstanarm':

laplace

Model Info:

function: stan\_glm

family: binomial [logit] formula: prop\_success ~ Tx

algorithm: sampling

sample: 4000 (posterior sample size)
priors: see help('prior\_summary')

observations: 2
predictors: 2

Estimates:

mean sd 10% 50% 90% (Intercept) -1.5987 0.2265 -1.8906 -1.5963 -1.3088 TxeCPR 0.1542 0.0501 0.0897 0.1535 0.2181

Fit Diagnostics:

mean sd 10% 50% 90% mean\_PPD 11.9740 3.1650 8.0000 12.0000 16.0000

The mean\_ppd is the sample average posterior predictive distribution of the outcome variable (for deta

MCMC diagnostics

mcse Rhat n\_eff (Intercept) 0.0042 0.9995 2872 TxeCPR 0.0009 0.9999 2827 mean\_PPD 0.0544 0.9994 3387 log-posterior 0.0238 1.0006 1835

For each parameter, mcse is Monte Carlo standard error, n\_eff is a crude measure of effective sample s

Have obviously not done this correctly as the prior should have shifted the default model parameter for eCPR to a larger number with a small sd

# 6. Figures

Warning: Removed 9 rows containing missing values (`stat\_slabinterval()`).

Warning: Using the `size` aesthietic with geom\_segment was deprecated in ggplot2 3.4.0. i Please use the `linewidth` aesthetic instead.

Figure 1 INCEPTION ITT analysis with vague prior





Figure 2 Beta Distribution of prior studies



 $\begin{aligned} \text{Green} &= p(\text{+outcome} \mid \text{eCPR}) \\ \text{Red} &= p(\text{+outcome} \mid \text{CPR}) \\ \text{Black= difference of the 2 probabilities} \end{aligned}$ 

#### References

- [1] M. M. Suverein, T. S. Delnoij, R. Lorusso, G. J. Brandon Bravo Bruinsma, L. Otterspoor, C. V. Elzo Kraemer, A. P. Vlaar, J. J. van der Heijden, E. Scholten, C. den Uil, T. Jansen, B. van den Bogaard, M. Kuijpers, K. Y. Lam, J. M. Montero Cabezas, A. H. Driessen, S. Z. Rittersma, B. G. Heijnen, D. Dos Reis Miranda, G. Bleeker, J. de Metz, R. S. Hermanides, J. Lopez Matta, S. Eberl, D. W. Donker, R. J. van Thiel, S. Akin, O. van Meer, J. Henriques, K. C. Bokhoven, L. Mandigers, J. J. Bunge, M. E. Bol, B. Winkens, B. Essers, P. W. Weerwind, J. G. Maessen, M. C. van de Poll, Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest, New England Journal of Medicine 388 (4) (2023) 299–309. doi:10.1056/NEJMoa2204511.
- [2] R. Wasserstein, A. Schirm, N. Lazar, Moving to a world beyond "p < 0.05", The American Statistician 73 (2019) 1–19.
- J. M. Brophy, Bayesian analyses of cardiovascular trials—bringing added value to the table, Canadian Journal of Cardiology 37 (9) (2021) 1415-1427. doi:https://doi.org/10.1016/j.cjca.2021.03.014.
   URL https://www.sciencedirect.com/science/article/pii/S0828282X2100163X
- [4] F. G. Zampieri, J. D. Casey, M. Shankar-Hari, F. E. Harrell, M. O. Harhay, Using bayesian methods to augment the interpretation of critical care trials. an overview of theory and example reanalysis of the alveolar recruitment for acute respiratory distress syndrome trial, American Journal of Respiratory and Critical Care Medicine 203 (5) (2021) 543-552, pMID: 33270526. arXiv:https://doi.org/10.1164/rccm.202006-2381CP, doi:10.1164/rccm.202006-2381CP. URL https://doi.org/10.1164/rccm.202006-2381CP
- [5] Stan Development Team, RStan: the R interface to Stan, r package version 2.28.1 (2021). URL http://mc-stan.org/5
- [6] S. L. Brilleman, E. M. Elci, J. B. Novik, R. Wolfe, Bayesian survival analysis using the rstanarm r package (2020). arXiv: 2002.09633.
  - URL https://arxiv.org/abs/2002.09633
- [7] J. Belohlavek, J. Smalcova, D. Rob, O. Franek, O. Smid, M. Pokorna, J. Horak, V. Mrazek, T. Kovarnik, D. Zemanek, A. Kral, S. Havranek, P. Kavalkova, L. Kompelentova, H. Tomkova, A. Mejstrik, J. Valasek, D. Peran, J. Pekara, J. Rulisek, M. Balik, M. Huptych, J. Jarkovsky, J. Malik, A. Valerianova, F. Mlejnsky, P. Kolouch, P. Havrankova, D. Romportl, A. Komarek, A. Linhart, O. S. G. Prague, Effect of intra-arrest transport, extracorporeal cardiopulmonary resuscitation, and immediate invasive assessment and treatment on functional neurologic outcome in refractory out-of-hospital cardiac arrest: A randomized clinical trial, JAMA 327 (8) (2022) 737–747. doi:10.1001/jama.2022.1025. URL https://www.ncbi.nlm.nih.gov/pubmed/35191923
- [8] D. Yannopoulos, J. Bartos, G. Raveendran, E. Walser, J. Connett, T. A. Murray, G. Collins, L. Zhang, R. Kalra, M. Kosmopoulos, R. John, A. Shaffer, R. J. Frascone, K. Wesley, M. Conterato, M. Biros, J. Tolar, T. P. Aufderheide, Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (arrest): a phase 2, single centre, open-label, randomised controlled trial, Lancet 396 (10265) (2020) 1807–1816. doi:10.1016/S0140-6736(20)32338-2. URL https://www.ncbi.nlm.nih.gov/pubmed/33197396
- [9] R. McElreath, Statistical Rethinking: A Bayesian Course with Examples in R and Stan, Chapman and Hall/CRC, 2020.